{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy","dispersionType":"Standard Error","groups":[{"description":"Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"MDX-010"}],"paramType":"MEAN","populationDescription":"The analysis population contains patients that had peripheral blood available for analysis from before and 1 month after initiating therapy along with being able to conduct the analysis on the marker. This resulted in the number of participants analyzed being less than the enrolled participants.","reportingStatus":"POSTED","timeFrame":"Before treatment to 1 month after therapy initiation","title":"Mean Change in % of CD3+CD4- for the Marker CD45RO+","type":"SECONDARY","unitOfMeasure":"percentage of change of CD3+CD4-"}